ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1537

Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis

Line Iversen1, Ole Østergaard2, Tina Friis3, susanne Ullman4, Søren Jacobsen5 and Jesper Olsen2, 1Department of Dermatology, Odense University Hospital., Odense, Denmark, 2Novo Nordisk Foundation Center for Protein Research, Copenhagen University, Copenhagen, Denmark, 3Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, 4Department of Dermatology, Bispebjerg, Copenhagen University Hospitals, Copenhagen, Denmark, 5Department of Rheumatology, Rigshospitalet, Copenhagen University Hospitals, Copenhagen, Denmark

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Mitochondrial Dysfunction, proteomics, Scleroderma, Systemic, skin

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Clinical Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: In the current work, we used a mass spectrometry based proteomics workflow to analyze isolated plasma microvesicles from systemic sclerosis (SSc) patients and from controls to search for biomarkers showing diagnostic and prognostic potential and correlation with disease severity and co-morbidities. SSc is a heterogenic autoimmune connective tissue disease affecting the skin and inner organs. High degree of morbidity and increased mortality is associated with the disease. Early diagnosis is crucial for intervening therapy. Yet, diagnosis as well as prognosis may be a challenge in systemic sclerosis and therapy may only delay—but not stop—the progression of the disease.

Methods: Microvesicles were isolated from 1 mL citrate plasma by ultracentrifugation (20,000xg, 30 min) followed by supernatant removal, addition of PBS and repeated ultracentrifugation to wash out plasma proteins (in total 4 washes). The final pellet was mixed with 8 M urea with DTT and IAA and digested using eLysC and trypsin. A fixed volume aliquot (approx. 500 ng peptides) were loaded onto EvoTips and analyzed using an Exploris 480 system equipped with an EvoSep LC-system. Peptides were eluted using a 45 min gradient and analyzed by data independent acquisition covering peptides in the range from 361-1033 Da. Collected RAW-files were analyzed using Spectronaut v16 using MS2 fragment intensities for quantification. Subsequent data analysis were performed using Perseus and R-studio.

Results: Thirty-eight plasma samples from patients diagnosed with scleroderma were compared with 25 samples collected from age and sex matched healthy controls. In total, almost 3000 proteins were quantified demonstrating the power of isolating microvesicles from plasma samples in order to obtain high analytical depth despite the challenges associated with the high dynamic range spanned by plasma proteins. After excluding 3 samples with less than 1750 proteins quantified, and removal of proteins quantified in less than 70 % of all samples, the dataset still included 2690 quantified proteins which were subject for further analysis. Among these proteins 752 proteins showed significantly differential abundance between patient and control samples. Review of published literature on biomarkers for SSc resulted in a list of 67 putative protein biomarkers in plasma. Among these 23 of the putative biomarkers were also quantified in the current dataset and the data showed significant differences in abundance between SSc patients and controls for 12 of these proteins. Among the proteins showing significant differential abundance were thrombospondin-1, thrombospondin-4, cartilage oligomeric matrix protein and CD47. This is particularly interesting as these proteins are part of a tight protein network involved in synthesis of NO. NO and associated downstream signaling is important for vasodilation of the small capillaries and is associated with Raynaud’s phenomenon – a symptom often observed years before diagnosis of systemic scleroderma.

Conclusion: The study gives insight into pathogenic processes in SSc as manifested in plasma and expand the panel of SSc biomarkers.


Disclosures: L. Iversen, None; O. Østergaard, None; T. Friis, None; s. Ullman, None; S. Jacobsen, None; J. Olsen, None.

To cite this abstract in AMA style:

Iversen L, Østergaard O, Friis T, Ullman s, Jacobsen S, Olsen J. Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/proteomic-profiling-of-plasma-microvesicles-isolated-from-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proteomic-profiling-of-plasma-microvesicles-isolated-from-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology